Satya Prakash Atmakuri, MD
Interventional Cardiology · Mesa, AZNPI 1598979668
Payments from drug & device makers
What this record shows
27 manufacturers reported payments, led by Medtronic at 39.2% of the total. 2025 is the largest year on record at $14,148, 5.4 times the $2,633 reported in 2019.
Across 356 payments — averaging $114.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Edwards Lifesciences$7K
- Abbott$5K
- Abiomed$5K
- Boston Scientific$2K
- AstraZeneca$784
- plus $5K from 21 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Travel & lodging$16,39740%
- Food & beverage$24,20060%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 61 | $15,922 |
| Edwards Lifesciences | 58 | $6,521 |
| Abbott | 110 | $5,437 |
| Abiomed | 41 | $5,347 |
| Boston Scientific | 21 | $1,679 |
| AstraZeneca | 8 | $784 |
| Shockwave Medical, Inc | 6 | $767 |
| Amgen | 6 | $517 |
| Impulse Dynamics (USA) Inc. | 3 | $509 |
| Teleflex LLC | 4 | $423 |
| Cardiovascular Systems Inc. | 4 | $405 |
| Recor Medical Inc | 2 | $290 |
| Philips North America LLC | 3 | $256 |
| Heartflow, Inc. | 3 | $236 |
| Novartis | 2 | $215 |
| Livanova USA, Inc. | 2 | $184 |
| Terumo Medical Corporation | 2 | $175 |
| Surmodics, Inc. | 1 | $158 |
| Bard Peripheral Vascular, Inc. | 3 | $157 |
| E.r. Squibb & Sons, L.L.C. | 2 | $140 |
| Biotronik Inc. | 1 | $123 |
| Asahi Intecc USA, Inc. | 2 | $114 |
| Tactile Systems Technology Inc | 5 | $78 |
| Koya Medical, Inc. | 1 | $62 |
| EKOS Corporation | 3 | $48 |
| GE HealthCare | 1 | $29 |
| Cvrx, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$4,308
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,509
- COREVALVE EVOLUT R$1,413
- RESOLUTE ONYX$1,207
- EVOQUE$1,130
- OPTIMIZER$1,017
- MitraClip$695
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$669
- Reveal LINQ$638
- MitraClip System$608
- PASCAL$584
- SYMPLICITY G3$574
- SAPIEN 3 Ultra RESILIA$493
- CoreValve Evolut$394
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$384
- FARXIGA$354
- CARDIOMEMS$315
- Repatha$301
- PORTICO$294
- AVVIGO Guidance System$260
How this compares
$40,597 in reported general payments places this provider in the 80th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 688 | $959,832 |
| Repatha SureclickEvolocumab | 294 | $267,653 |
| XareltoRivaroxaban | 162 | $187,213 |
| EntrestoSacubitril/Valsartan | 138 | $167,574 |
| FarxigaDapagliflozin Propanediol | 137 | $165,263 |
| Praluent PenAlirocumab | 61 | $52,924 |
| BrilintaTicagrelor | 51 | $50,609 |
| Repatha SyringeEvolocumab | 29 | $25,638 |
| Rosuvastatin Calcium | 890 | $15,103 |
| ClopidogrelClopidogrel Bisulfate | 864 | $10,629 |
| Midodrine Hcl | 110 | $7,801 |
| Atorvastatin Calcium | 682 | $6,858 |
| Metoprolol Succinate | 577 | $6,163 |
| Valsartan | 168 | $6,117 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 437 | $5,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $784 | $215,873188 claims |
| NovartisEntresto | $215 | $167,574138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Mesa
- Faraj KargoliMesa$115K
- Nachiket PatelMesa$107K
- Robert CandipanMesa$32K
- I-Hui ChiangMesa$27K
- Paul SorajjaPhoenix$1.1M
- Hursh NaikAvondale$781K
- Thomas WaggonerTucson$617K
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
- Kapildeo LotunTucson$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.